Navigation Links
Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
Date:1/12/2009

SHELTON, Conn., Jan. 12 /PRNewswire/ -- Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist, CR845. The Phase II multi-center, double-blind, placebo-controlled trial will be conducted in the United States and will evaluate the analgesic efficacy and safety of intravenous CR845 during the post-operative period in women following laparoscopic-assisted hysterectomy. The trial is expected to enroll 120 patients, who will be randomly selected for treatment with one of two doses of CR845 or placebo. Results from the study are expected in the second half of 2009.

The Company also expects to initiate a Phase I study of an oral formulation of CR845 later in 2009.

About CR845

A previous Phase Ia single-center clinical trial of intravenous CR845 evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of the compound in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown to be safe at all doses investigated, with no reports of serious side effects or adverse central nervous system activity. Linear, dose-proportional increases in systemic exposure to CR845 were observed. Low doses of CR845 stimulated physiological biomarkers of peripheral kappa opioid receptor activity, and also produced plasma levels of drug associated with analgesic efficacy in multiple preclinical studies.

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibited analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Oral bioavailability was confirmed in multiple species. In contrast to currently marketed opioids, CR845 did not produce inhibition of intestinal transit (ileus) or elicit signs of abuse or addiction liability in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements may include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward-looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
9. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... Buyers and sellers ... users to dispensaries and head shops –can’t help but be heartened by the industry’s ... tell-tale cannabis odor aptly described as “skunk smell.” At last they can simply, ...
(Date:4/25/2017)... Hollywood, Fl (PRWEB) , ... April 25, 2017 , ... ... than Memorial Regional Hospital, according to a special report in the May issue of ... Hospital its highest quality ranking for results achieved during and after coronary bypass ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... , ... As part of the nationwide Days of Remembrance effort led by ... and Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced that ... to Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip to ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
Breaking Medicine News(10 mins):